New targeted cancer drug enters first human tests
NCT ID NCT07567859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called HS-10587 in people with advanced solid tumors that have lost a gene called MTAP. The study aims to find a safe dose and see if the drug can shrink tumors. About 362 participants who have exhausted standard treatments will take the drug as a tablet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-10587 tablet
What this could lead to
If this early study shows promise, HS-10587 could become a new treatment option for people with certain hard-to-treat cancers that have a specific genetic change (MTAP deletion).
What could go wrong
This is a very early Phase 1 trial, so the drug may not work or could have serious side effects. It is only for people who have already tried other treatments, and the results may not apply to all cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MTAP DELETION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.